AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

There’s really no such thing as a “no brainer” stock pick. I’d say that some opportunities are more compelling than others.

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a ...